Having hived off its animal health vaccine manufacturing and R&D to France’s Ceva, IDT Biologika is focused entirely on human products. To propel that effort, it has opened a new vaccine manufacturing facility in Germany. More: IDT Biologika opens vaccine manufacturing
read moreIt’s been just over 16 months since Sanofi closed its $11.6 billion buyout of hemophilia specialist Bioverativ. But the company is already revising its sales projections for one of Bioverativ’s key products—big-time. More: Sanofi takes B hemophilia write-down as Roche's
read moreSanofi doesn’t see much of a future for diabetes drug Zynquista, so it’s exiting a development partnership. But Lexicon is hitting back by saying the company hasn’t fulfilled its obligations. More: Sanofi dumps Zynquista collab following phase 3 failures, but
read moreNovartis granting Sandoz its independence within the company sounds a lot like what Pfizer did before striking its deal to merge Upjohn with generics maker Mylan. But to hear Novartis CEO Vas Narasimhan tell it, his company won’t go down
read moreEntresto’s blockbuster turn in 2018 was a long time coming for Novartis, which held on to a $5 billion vision for the drug even as its launch lagged. Those dreams took another hit Monday when Entresto flopped a phase 3
read moreThe sales numbers were boosted by oncology drugs such as Tagrisso, Imfinzi and Lynparza. More: AZ presents strong H1 financial results Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals